Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Harvard Apparatus Regenerative Technology Inc's Business Segments
Harvard Apparatus Regenerative Technology Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
1
Largest Segment
Consumer Health Products
Total Revenue
$ 0
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Consumer Health Products100%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Consumer Health Products | $ 0 | 100% |
Description of Harvard Apparatus Regenerative Technology Inc
Harvard Apparatus Regenerative Technology Inc., commonly known as HART, is a pioneering biomedical company that specializes in the development and commercialization of regenerative medicine technologies. The company was founded in 2004 and is based in Holliston, Massachusetts, USA.
HART is a subsidiary of Harvard Bioscience, a globally recognized manufacturer and developer of advanced instruments and systems for life science research. The company primarily focuses on tissue engineering and organ regeneration, aiming to provide innovative solutions for patients suffering from various degenerative diseases and injuries.
One of the key areas of expertise for HART is the development of bioengineered organs and tissues. They have made significant advancements in the field of regenerative medicine, leveraging their deep understanding of biology, materials science, and engineering. By combining these domains, HART aims to create functional replacement organs that can overcome the limitations of traditional transplantation.
The company's flagship technology is the InBreath™ bioartificial lung, which focuses on providing respiratory support to patients with acute lung failure. The InBreath™ device incorporates living cells to mimic the structure and function of the lung, allowing for better gas exchange and improved patient outcomes compared to conventional ventilation methods.
In addition to the InBreath™ bioartificial lung, HART also works on developing regenerative medicine solutions for other organs, such as the heart, liver, kidney, and pancreas. They employ innovative techniques and materials to create scaffolds and support structures that enable cell growth and integration, ultimately leading to the formation of fully functional, healthy organs.
HART collaborates with leading academic and research institutions, medical centers, and biotechnology companies to advance the field of regenerative medicine. Their partnerships allow for the exchange of expertise, access to diverse resources, and the collective effort to drive innovation in the areas of tissue engineering, regenerative therapies, and organ transplantation.
The company's commitment to innovation is further demonstrated by its investment in research and development activities. HART consistently explores cutting-edge technologies and techniques to enhance the efficacy, safety, and scalability of their regenerative medicine solutions. Their goal is to bring transformative products to patients and medical practitioners, positively impacting lives and revolutionizing healthcare.
HART also places significant emphasis on regulatory compliance and manufacturing excellence. They adhere to rigorous quality standards, both in their research and development processes and in the production of their bioartificial organs and tissues. This commitment ensures the safety, efficacy, and reliability of their products, as well as compliance with applicable regulatory requirements.
In summary, Harvard Apparatus Regenerative Technology Inc. is a leading biomedical company focused on the development and commercialization of regenerative medicine technologies. Through innovative research, partnerships, and a commitment to quality, HART aims to revolutionize the field of regenerative medicine and improve the lives of patients suffering from degenerative diseases and injuries.
HART is a subsidiary of Harvard Bioscience, a globally recognized manufacturer and developer of advanced instruments and systems for life science research. The company primarily focuses on tissue engineering and organ regeneration, aiming to provide innovative solutions for patients suffering from various degenerative diseases and injuries.
One of the key areas of expertise for HART is the development of bioengineered organs and tissues. They have made significant advancements in the field of regenerative medicine, leveraging their deep understanding of biology, materials science, and engineering. By combining these domains, HART aims to create functional replacement organs that can overcome the limitations of traditional transplantation.
The company's flagship technology is the InBreath™ bioartificial lung, which focuses on providing respiratory support to patients with acute lung failure. The InBreath™ device incorporates living cells to mimic the structure and function of the lung, allowing for better gas exchange and improved patient outcomes compared to conventional ventilation methods.
In addition to the InBreath™ bioartificial lung, HART also works on developing regenerative medicine solutions for other organs, such as the heart, liver, kidney, and pancreas. They employ innovative techniques and materials to create scaffolds and support structures that enable cell growth and integration, ultimately leading to the formation of fully functional, healthy organs.
HART collaborates with leading academic and research institutions, medical centers, and biotechnology companies to advance the field of regenerative medicine. Their partnerships allow for the exchange of expertise, access to diverse resources, and the collective effort to drive innovation in the areas of tissue engineering, regenerative therapies, and organ transplantation.
The company's commitment to innovation is further demonstrated by its investment in research and development activities. HART consistently explores cutting-edge technologies and techniques to enhance the efficacy, safety, and scalability of their regenerative medicine solutions. Their goal is to bring transformative products to patients and medical practitioners, positively impacting lives and revolutionizing healthcare.
HART also places significant emphasis on regulatory compliance and manufacturing excellence. They adhere to rigorous quality standards, both in their research and development processes and in the production of their bioartificial organs and tissues. This commitment ensures the safety, efficacy, and reliability of their products, as well as compliance with applicable regulatory requirements.
In summary, Harvard Apparatus Regenerative Technology Inc. is a leading biomedical company focused on the development and commercialization of regenerative medicine technologies. Through innovative research, partnerships, and a commitment to quality, HART aims to revolutionize the field of regenerative medicine and improve the lives of patients suffering from degenerative diseases and injuries.
Harvard Apparatus Regenerative Technology Inc. (HART) specializes in the development of regenerative medicine technologies, particularly in the areas of tissue engineering, organ regeneration, and cellular therapies. The company has focused on innovative solutions aimed at addressing critical medical needs through advanced scientific research and product development. Here are the key segments, products, and services that HART typically offers:
Segments
1. Tissue Engineering:
- HART is engaged in the creation of biological tissues using engineering techniques. This can involve the development of scaffold materials designed to support cell growth and tissue formation.
2. Organ Regeneration:
- The company focuses on technologies that promote organ regeneration, with the goal of creating functional organ replacements or augmenting existing organ function.
3. Cell Therapies:
- HART develops products related to stem cell therapies and other cellular applications aimed at enhancing the healing process in various medical conditions.
Products
1. Decellularized Tissue Products:
- HART is known for its decellularized products, which are derived from animal or human tissues that have been treated to remove cells while preserving the extracellular matrix. These products can be used as scaffolds for tissue regeneration.
2. Regenerative Biomaterials:
- The company offers a range of biomaterials designed to promote cellular integration and tissue healing. These materials may be engineered to provide specific mechanical properties and support cellular activities.
3. 3D Bioprinting Technology:
- HART incorporates 3D printing technologies to create complex tissue structures. This process allows for precise placement of cells and materials, mimicking natural tissue architecture.
4. Preclinical Models:
- HART develops preclinical models for testing regenerative technologies before clinical application. These models help in understanding the biological responses and efficacy of treatments.
5. Custom Tissue Engineering Solutions:
- The company provides custom solutions tailored to meet specific research or clinical needs. This may include creating unique scaffold designs or specialized tissue constructs for particular applications.
Services
1. Consulting and Collaborations:
- HART offers consulting services to partners in the healthcare domain. This could involve collaborating on research and development projects, sharing expertise in tissue engineering and regenerative medicine.
2. Research and Development Support:
- The firm may provide R&D services aimed at advancing the field of regenerative medicine. This includes conducting studies to evaluate bioactivity, efficacy, and safety of new technologies.
3. Regulatory and Clinical Pathway Guidance:
- HART assists organizations in navigating the complex regulatory landscape surrounding regenerative medicine products. This includes providing guidance on preclinical testing, clinical trial design, and regulatory submissions.
4. Educational Resources:
- The company may also provide training and workshops aimed at educating researchers and clinicians on the latest techniques and applications in tissue engineering and regenerative medicine.
Conclusion
Through its innovative products and comprehensive services, Harvard Apparatus Regenerative Technology Inc. aims to advance the field of regenerative medicine, addressing unmet medical needs and improving patient outcomes. The integration of cutting-edge research with practical applications sets the stage for the companys ongoing mission in developing effective regenerative therapies.
Segments
1. Tissue Engineering:
- HART is engaged in the creation of biological tissues using engineering techniques. This can involve the development of scaffold materials designed to support cell growth and tissue formation.
2. Organ Regeneration:
- The company focuses on technologies that promote organ regeneration, with the goal of creating functional organ replacements or augmenting existing organ function.
3. Cell Therapies:
- HART develops products related to stem cell therapies and other cellular applications aimed at enhancing the healing process in various medical conditions.
Products
1. Decellularized Tissue Products:
- HART is known for its decellularized products, which are derived from animal or human tissues that have been treated to remove cells while preserving the extracellular matrix. These products can be used as scaffolds for tissue regeneration.
2. Regenerative Biomaterials:
- The company offers a range of biomaterials designed to promote cellular integration and tissue healing. These materials may be engineered to provide specific mechanical properties and support cellular activities.
3. 3D Bioprinting Technology:
- HART incorporates 3D printing technologies to create complex tissue structures. This process allows for precise placement of cells and materials, mimicking natural tissue architecture.
4. Preclinical Models:
- HART develops preclinical models for testing regenerative technologies before clinical application. These models help in understanding the biological responses and efficacy of treatments.
5. Custom Tissue Engineering Solutions:
- The company provides custom solutions tailored to meet specific research or clinical needs. This may include creating unique scaffold designs or specialized tissue constructs for particular applications.
Services
1. Consulting and Collaborations:
- HART offers consulting services to partners in the healthcare domain. This could involve collaborating on research and development projects, sharing expertise in tissue engineering and regenerative medicine.
2. Research and Development Support:
- The firm may provide R&D services aimed at advancing the field of regenerative medicine. This includes conducting studies to evaluate bioactivity, efficacy, and safety of new technologies.
3. Regulatory and Clinical Pathway Guidance:
- HART assists organizations in navigating the complex regulatory landscape surrounding regenerative medicine products. This includes providing guidance on preclinical testing, clinical trial design, and regulatory submissions.
4. Educational Resources:
- The company may also provide training and workshops aimed at educating researchers and clinicians on the latest techniques and applications in tissue engineering and regenerative medicine.
Conclusion
Through its innovative products and comprehensive services, Harvard Apparatus Regenerative Technology Inc. aims to advance the field of regenerative medicine, addressing unmet medical needs and improving patient outcomes. The integration of cutting-edge research with practical applications sets the stage for the companys ongoing mission in developing effective regenerative therapies.